Enzon Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Enzon Pharmaceuticals, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial statement components and stock information.</b>

AI Summary

ENZON PHARMACEUTICALS, INC. (ENZN) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Enzon Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to Series C Preferred Stock and Common Stock as of various dates in 2022, 2023, and 2024. Key financial statement components like Retained Earnings and Additional Paid-In Capital are detailed for periods ending March 31, 2024, December 31, 2023, March 31, 2023, and December 31, 2022. The report references research activities in the domestic country as of March 31, 2024. Information regarding the New Jersey Division of Taxation is included for Q1 2024 and Q1 2023.

Why It Matters

For investors and stakeholders tracking ENZON PHARMACEUTICALS, INC., this filing contains several important signals. This filing provides an update on Enzon's financial position and equity structure, crucial for investors to assess the company's stability and growth potential. The inclusion of specific dates and financial figures allows for year-over-year and quarter-over-quarter comparisons, aiding in performance analysis.

Risk Assessment

Risk Level: low — ENZON PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a standard 10-Q report, which typically contains routine financial information and does not indicate significant new risks or events.

Analyst Insight

Investors should review the detailed financial statements and equity changes in the 10-Q to understand Enzon's current financial health and any potential implications for future performance.

Key Numbers

• 2024-03-31 — Period of Report (Quarterly report filing)
• 2024-05-10 — Filing Date (Date the 10-Q was submitted)
• 2023-12-31 — Previous Year End (Reference date for financial comparisons)
• 2023-03-31 — Prior Year Q1 End (Reference date for year-over-year comparisons)

Key Players & Entities

• ENZON PHARMACEUTICALS, INC. (company) — Filer name
• ENZN (company) — Ticker symbol
• 2024-03-31 (date) — Period of report
• 2024-05-10 (date) — Filing date
• Series C Preferred Stock (security) — Mentioned in relation to equity structure
• New Jersey Division of Taxation (regulator) — Mentioned in relation to tax information

FAQ

Industry Context

Enzon Pharmaceuticals operates in the biotechnology sector, focusing on the development and commercialization of pharmaceutical products.

Regulatory Implications

The filing is a standard 10-Q, adhering to SEC regulations for quarterly reporting by public companies.

What Investors Should Do

1. Review the balance sheet details for changes in equity and liabilities.
2. Analyze the retained earnings and additional paid-in capital trends.
3. Note any specific disclosures related to the New Jersey Division of Taxation.

Key Dates

• 2024-03-31: Quarter End — End of the reporting period for the 10-Q
• 2024-05-10: Filing Date — Date the 10-Q was officially submitted to the SEC

Year-Over-Year Comparison

This 10-Q filing provides updated financial data for the quarter ending March 31, 2024, compared to previous periods like Q1 2023 and year-end 2023.

Filing Documents

• enzn-20240331x10q.htm (10-Q) — 582KB
• enzn-20240331xex31d1.htm (EX-31.1) — 15KB
• enzn-20240331xex32d1.htm (EX-32.1) — 6KB
• 0001410578-24-000735.txt (&nbsp;) — 2871KB
• enzn-20240331.xsd (EX-101.SCH) — 31KB
• enzn-20240331_cal.xml (EX-101.CAL) — 19KB
• enzn-20240331_def.xml (EX-101.DEF) — 97KB
• enzn-20240331_lab.xml (EX-101.LAB) — 220KB
• enzn-20240331_pre.xml (EX-101.PRE) — 170KB
• enzn-20240331x10q_htm.xml (XML) — 252KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 18 Item 4.

Controls and Procedures

Controls and Procedures 18

– OTHER INFORMATION

PART II – OTHER INFORMATION 19 Item 1.

Legal Proceedings

Legal Proceedings 19 Item 1A.

Risk Factors

Risk Factors 19 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19 Item 3. Defaults Upon Senior Securities 19 Item 4. Mine Safety Disclosures 19 Item 5. Other Information 19 Item 6. Exhibits 19

Signatures

Signatures 20 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) March 31, December 31, 2024 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 45,988 $ 47,012 Other current assets 481 331 Total current assets 46,469 47,343 Deferred tax asset 360 359 Total assets $ 46,829 $ 47,702 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 331 $ 331 Accrued expenses and other current liabilities 190 108 Dividends payable on Series C preferred stock — 1,275 Total current liabilities 521 1,714 Commitments and contingencies Mezzanine equity: Series C preferred stock - $ 0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value $ 1,075 and $ 1,062 per share) at March 31, 2024 and December 31, 2023 43,014 42,483 Stockholders' equity: Preferred stock - $ 0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock - $ 0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at March 31, 2024 and December 31, 2023 742 742 Additional paid-in capital 72,902 73,433 Accumulated deficit ( 70,350 ) ( 70,670 ) Total stockholders' equity 3,294 3,505 Total liabilities, mezzanine equity and stockholders' equity $ 46,829 $ 47,702 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Three months ended March 31, 2024 2023 Revenues: Royalties and milestones, net $ — $ — Total revenues — — Operating expenses: General and administrative 326 285 Total operating expenses 326 28

View Full Filing

View this 10-Q filing on SEC EDGAR